131.15
131.15 (0%)
As of Feb 14, 2025
Axsome Therapeutics, Inc. [AXSM]
Source:
Company Overview
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and delivery of transformative medicines for people impacted by central nervous system, or CNS, conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | (212) 332-3241 |
| Industry | manufacturing |
| CEO | Herriot Tabuteau |
| Website | www.axsome.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $385.7 |
| Operating Profit | $-280.6 |
| Net Income | $-287.2 |
| Net Cash | $-70.8 |
Profit Ratios
| Gross Margin | $352.4 |
| Operating Margin | -72.7 |
| Profit as % of Revenues | -122.7% |
| Profit as % of Assets | -49.7% |
| Profit as % of Stockholder Equity | -503.8% |
Management Effectiveness
| Return on Equity | -503.8% |
| Return on Assets | -50.5% |
| Turnover Ratio | 66.7% |
| EBITA | $-274.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $568.5 |
| Total Liabilities | $511.5 |
| Operating Cash Flow | $-128.4 |
| Investing Cash Flow | $-0.3 |
| Financing Cash Flow | $57.8 |
